A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
39
Participants
Timeline
Start Date
July 31, 2014
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Conditions
Schizophrenia
Interventions
DRUG
SKL15508
DRUG
Placebo
Trial Locations (1)
91206
Glendale Adventist Medical Center, Glendale
All Listed Sponsors
lead
SK Life Science, Inc.
INDUSTRY
NCT02205099 - A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia | Biotech Hunter | Biotech Hunter